BBIO (BridgeBio Corp) Forward P/S Multiple

Corporate emblem and logo of BridgeBio Pharma, Inc. (BBIO)

The use of AI for drug discovery is accelerating the development of BridgeBio Pharma, Inc. (BBIO), which is reflected in the asset dynamics. The forward P/S metric demonstrates current market expectations, with the indicator reaching the level of 16.20. Stability is ensured by the insulation of Western markets from sanctions and the implementation of environmental standards in laboratories, which minimizes risks and supports the long-term value of the business.

BridgeBio - BBIO Forward P/S Multiple (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for BridgeBio Corp (BBIO)

- market price and analyst price targets:
Price Chart BridgeBio|BBIO - Forecast Levels Chart
- business market valuation indicators:
Market Capitalization BridgeBio Corp|BBIO - Value Adjusted for Debt and Cash
- issuer book value statistics:
Book Value per Share BridgeBio|BBIO - Book Capitalization|Market Value to Book Value Ratio bridgebio.com|BBIO - Aggregate Asset Value
- debt and solvency information:
Debt to Equity BridgeBio Pharma, Inc.|BBIO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital BridgeBio Pharma, Inc.|BBIO - Company Aggregate Debts|Debts to Book Capitalization BridgeBio Corp|BBIO - Company Long-Term Debt|Company Short-Term Debt BridgeBio|Quick Ratio bridgebio.com
- financial results and valuation multiples details:
BBIO - Net Financial Result|Projected Future Earnings BridgeBio Pharma, Inc.|BBIO - Price to Earnings Multiple|Forward P/E Multiple BridgeBio Pharma Inc|BBIO - Price to Net Income Growth Ratio|EV/EBITDA Multiple BridgeBio Corp|BBIO - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) BridgeBio|BBIO - Earnings per share for the last twelve months|Quarterly EPS earnings growth bridgebio.com|BBIO - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year BridgeBio Pharma, Inc.
- total revenue and sales volume data:
BBIO - Company Total Revenue|Company Future Sales Volume BridgeBio|BBIO - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio BridgeBio Corp
Fundamental company analysis:BridgeBio BBIO
Original product of BridgeBio Corp

Forward P/S assesses the market value of a business relative to its projected revenue, allowing an investor to determine the degree of an asset's overvaluation. By analyzing the expected P/S multiple on the GURU.Markets platform, one can promptly identify a reduction in the capital's margin of safety. This indicator correlates market capitalization with sales potential, which is critical for BridgeBio Pharma, Inc. (BBIO), as the company minimizes risks through the simultaneous development of multiple independent genetic drugs.

Who BridgeBio Pharma, Inc. competes with

Price-to-Projected Revenue Ratio Vertex VRTX|ALNY (Alnylam Pharmaceuticals, Inc.) - Future Price to Revenue|Insmed Inc - Forward P/S Multiple|Forward Price to Sales UTHR (United Therapeutics Inc.)|BMRN: Forward P/S Multiple|BGM Group (BGM) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Cogent Biosciences, Inc.|XERS: Forward Price to Sales|Price-to-Projected Revenue Ratio Keros Pharma (KROS)|Forward Price-to-Revenue Multiple Arcturus Corp ARCT|Forward P/S Multiple ETON (Eton Pharmaceuticals)|Forward P/S Multiple kamada.com KMDA|Fulcrum Therapeutics, Inc. - Forward P/S Multiple|ABEO: Price-to-Projected Revenue Ratio|mereobiopharma.com (MREO) - Price-to-Projected Revenue Ratio|Protalix BioTherapeutics, Inc - Forward Price to Sales|PLRX (Pliant Therapeutics Inc) - Forward P/S Multiple|appliedtherapeutics.com (APLT) - Market Cap to Expected Sales Ratio|Forward P/S Multiple RNTX|gelteq.com - Market Cap to Projected Revenue|Forward P/S Multiple AYTU (Aytu BioPharma)|Projected Price to Revenue Chemomab Therapeutics Ltd|SRx Health - Forward P/S Multiple|Market Cap to Future Revenue Ratio Polyrizon Ltd|AEZS: Forward P/S Multiple|CYTH (Cyclo Therapeutics Inc.) - Price-to-Projected Revenue Ratio|INZY (Inozyme Pharma Inc.) - Forward P/S Multiple|Reneo Pharmaceuticals, Inc (RPHM) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio COSCIENS Biopharma Inc. (CSCI)